Breaking News

MilliporeSigma Opens Commercial Facility for New CTDMO Services

The 2,700-square-meter site in Martillac, France will provide global supply of commercial drug substances.

By: Kristin Brooks

Managing Editor, Contract Pharma

MilliporeSigma’s Life Science business sector has opened a commercial facility for its new Millipore CTDMO Services offering at the company’s site in Martillac, France. The 2,700-square-meter facility will provide global supply of commercial drug substances, including mAbs and other recombinant proteins. The integrated site features state-of-the-art single-use equipment and onsite regulatory, quality and technical experts.
 
“Our clients are pioneering modern medicine and managing multiple partners, supply chain needs and complex priorities and are turning to our company to help them navigate the complexity and provide flexibility and scale,” said Dirk Lange, Head of Life Science Services, Life Science business sector of Merck KGaA, Darmstadt, Germany. “With this facility and our global Millipore® CTDMO Services network, we offer truly differentiated services, including templates for drug development, manufacturing and commercialization to accelerate molecules to market with one experienced partner.”
 
This expansion will support clients such as Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company focusing on pediatric immunotherapies leveraging the company’s CTDMO services. “With the Life Science business sector’s support, we’ve brought our product candidate for pediatric brain cancer to patients in roughly half the time than the approximate 12 years it typically takes to bring a biologic to market,” said Torben Lund-Hansen, CTO, Head of Technical Operations, Y-mAbs.  “Their end-to-end process development and GMP manufacturing services were key to achieving this milestone.”
 
The Martillac facility is designed to operate at high efficiency levels and can rapidly pivot from 200 to 2000 liters of drug substance. It also features two 2000-liter bioreactors in one manufacturing suite to increase capacity and flexibility. The site aims to streamline and accelerate the commercialization process by eliminating the need for tech transfer and scale-up between clinical and commercial stages. This CTDMO services offering is purpose-built and integrates product characterization and safety testing to accelerate the development and commercialization process.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters